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Simple Summary: Transcription factor NRF2 controls expression of antioxidant and detoxification
genes. Normally, the activity of NRF2 is tightly controlled in the cell, and is continuously adjusted to
ensure that cells are protected against endogenous chemicals and environmental agents that perturb
the intracellular antioxidant/pro-oxidant balance (i.e., redox) that must be maintained for them to
grow and survive in an appropriate manner. This tight control of NRF2 is achieved by a repressor
protein called KEAP1 that perpetually targets NRF2 protein for degradation under normal conditions,
but is unable to do so when challenged with oxidants or thiol-reactive chemicals. In the context of
cancer, it is well known that drugs that stimulate short-term and reversible activation of NRF2 can
provide protection for a limited period against exposure to chemicals that cause cancer. However, it is
also becoming widely recognised that permanent hyper-activation of NRF2 resulting from somatic
mutations in the gene that encodes NRF2, or in genes associated with its degradation, is frequently
observed in certain cancers and associated with poor outcome. In this article, we provide a critical
overview of the literature describing the seemingly ambiguous contributions that NRF2 makes to
the development of cancer. In particular, we describe the range of genetic and other mechanisms
that are responsible for the upregulation of NRF2 in tumours, and highlight shortcomings in our
knowledge of how frequently this occurs in different types of cancer. Moreover, we discuss how
upregulation of NRF2 might aid the growth and survival of tumours, whether NRF2 upregulation in
particular types of cancer is associated with mutations in specific oncogenes, and at what stage of
cancer development this is likely to occur. Lastly, we discuss therapeutic strategies that have been
proposed that selectively target tumours in which NRF2 is permanently activated with a view to
overcoming NRF2-associated drug resistance.
Abstract: NF-E2 p45-related factor 2 (NRF2, encoded in the human by NFE2L2) mediates short-term
adaptation to thiol-reactive stressors. In normal cells, activation of NRF2 by a thiol-reactive stressor
helps prevent, for a limited period of time, the initiation of cancer by chemical carcinogens through
induction of genes encoding drug-metabolising enzymes. However, in many tumour types, NRF2 is
permanently upregulated. In such cases, its overexpressed target genes support the promotion
and progression of cancer by suppressing oxidative stress, because they constitutively increase
the capacity to scavenge reactive oxygen species (ROS), and they support cell proliferation by
increasing ribonucleotide synthesis, serine biosynthesis and autophagy. Herein, we describe cancer
chemoprevention and the discovery of the essential role played by NRF2 in orchestrating protection
against chemical carcinogenesis. We similarly describe the discoveries of somatic mutations in NFE2L2
and the gene encoding the principal NRF2 repressor, Kelch-like ECH-associated protein 1 (KEAP1) along
with that encoding a component of the E3 ubiquitin-ligase complex Cullin 3 (CUL3), which result in
permanent activation of NRF2, and the recognition that such mutations occur frequently in many types
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of cancer. Notably, mutations in NFE2L2, KEAP1 and CUL3 that cause persistent upregulation of NRF2
often co-exist with mutations that activate KRAS and the PI3K-PKB/Akt pathway, suggesting NRF2
supports growth of tumours in which KRAS or PKB/Akt are hyperactive. Besides somatic mutations,
NRF2 activation in human tumours can occur by other means, such as alternative splicing that results
in a NRF2 protein which lacks the KEAP1-binding domain or overexpression of other KEAP1-binding
partners that compete with NRF2. Lastly, as NRF2 upregulation is associated with resistance to cancer
chemotherapy and radiotherapy, we describe strategies that might be employed to suppress growth
and overcome drug resistance in tumours with overactive NRF2.
Keywords: NRF2; KEAP1; Cullin 3; ATF4; oxidative stress; reactive oxygen species; antioxidant;
adaptation; glutathione; thioredoxin; NADPH generation; pentose phosphate pathway; proteasome;
autophagy; drug metabolism; chemoprevention; chemotherapy; bioactivation; quinone-containing
drugs; drug resistance; oncogene; tumour suppressor; initiation; progression; metastasis; recurrent
disease; lung; oesophagus; liver; head and neck; stomach; bladder; colon; rectum
1. Introduction
The cap’n’collar (CNC) basic-region leucine zipper (bZIP) transcription factor NF-E2 p45-related
factor 2 (NRF2, encoded by NFE2L2) is a master regulator of intracellular redox homeostasis because,
in response to oxidative stress, it orchestrates induction of a battery of genes that serve to increase
the antioxidant capacity of the cell. Since oxidative stress is associated with many common chronic
debilitating ailments such as cancer, cardiovascular disease, diabetes mellitus, inflammatory disease,
liver cirrhosis, lung fibrosis and neurodegenerative disease, it is not surprising that pharmacological
agents that reversibly activate NRF2, and so alleviate oxidative stress, have been linked to the
prevention or attenuation of many of these conditions [1]. Paradoxically, however, in certain types
of cancer the irreversible genetic upregulation of NRF2 resulting from stochastic somatic activating
mutations in NFE2L2 or inactivating mutations in the gene encoding the repressor of NRF2, Kelch-like
ECH-associated protein 1 (KEAP1), or that for its E3 ligase Cullin 3 (CUL3), is associated with
progression of disease once it has been initiated [2]. In mammals, oxidative stress increases with age
and this is accompanied by increased susceptibility to degenerative disease, which is associated with
lower levels of intracellular antioxidants and the downregulation of NRF2 [3–5]. Considerable interest
therefore exists around the interplay between degenerative disease, oxidative stress and NRF2, and how
this can be exploited to improve health.
Although NRF2 was initially discovered by Yuet Wai Kan and colleagues as a human transcription
factor that shared homology with the p45 subunit of NF-E2 and was capable of binding a tandemly-arrayed
activator protein-1 (AP-1) recognition sequence (i.e., 5′-TGAGTCATGATGAGTCA-3′, with AP-1-binding
sites underlined) in the β-globin gene locus, its involvement in directing cellular adaptation to
oxidative stress was not immediately apparent [6,7]. This is possibly because many transcription
factors, including AP-1, Forkhead box O (FOXO), peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α), nuclear factor-kappaB (NF-κB) and tumour protein p53 (TP53),
control expression of antioxidant genes, and because NRF2 does not regulate directly the classic
antioxidant enzyme superoxide dismutase (SOD) 1 or SOD2, unlike some of these other transcription
factors [8]. Rather than being linked to the oxidative stress response, it was thought by various
researchers that since the DNA sequence bound by NRF2 resembles an antioxidant responsive element
(ARE, 5′-TGACNNNGC-3′) [9], also called an electrophile responsive element [10], the transcription
factor might mediate induction of genes for drug-metabolising enzymes. Of particular significance,
the DNA binding site also resembles a musculoaponeurotic fibrosarcoma (MAF) recognition element
(MARE, 5′-TGCTGAG/CTCAGCA-3′) [11], and so the family of small MAF bZIP proteins, which can
heterodimerize with NRF2, were considered as possible partners of NRF2 [12].
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Based on a mouse gene knockout (ko) model, the first physiological role of Nrf2 was reported by
Masi Yamamoto and colleagues to be that of mediating induction of drug-metabolising enzymes, in liver
and small intestine, by the phenolic antioxidant butylated hydroxyanisole (BHA), the genes of which
were known to contain ARE sequences in their regulatory regions; these included genes encoding
NAD(P)H:quinone oxidoreductase 1 (NQO1, also called NAD(P)H dehydrogenase (quinone 1),
and occasionally DT-diaphorase or menadione reductase) and various class Alpha, Mu and Pi
glutathione S-transferase (GST) subunits [13]. Moreover, these workers proposed that NRF2 binds
ARE/MARE sequences as a heterodimer with small MAF proteins, and this was later confirmed
using compound small Maf knockout mice [14]. Careful examination of tissue extracts from Nrf2-ko
mice revealed that the CNC-bZIP transcription factor controlled basal as well as inducible gene
expression [13,15]. Later, the phenolic antioxidant ethoxyquin, the benzopyran coumarin and the
related limettin (also called citropten), the butanolide α-angelica lactone, the dithiolethione oltipraz,
the diterpenes cafestol and kahweol, the isothiocyanate sulforaphane (SFN), and indole-3-carbinol
were all found to require the presence of Nrf2 to induce ARE-driven drug-metabolizing enzyme
genes [16–19]. Since then, more potent NRF2-dependent inducers designed around a triterpenoid
backbone, such as 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole and TBE-31, have been
described [20,21]. See Figure 1 for the structures of these inducing agents.
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Figure 1. Structures of xenobiotics that require Nrf2 to induce mouse Nqo1 and Gst genes. These include
butylated hydroxyanisole (BHA), ethoxyquin, coumarin, limettin, α-angelica lactone, oltipraz, cafestol,
kahweol, sulforaphane, indole-3-carbinol, 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole
(CDDO-Im) and TBE-31.
Following recognition that Nrf2 regulates Nqo1 and Gst subunit genes in the mouse, microarray
analyses by Tom Kensler and others revealed that many other drug-metabolizing enzymes,
including aldo-keto reductase (AKR), aldehyde dehydrogenase (ALDH), carbonyl reductase (CBR1),
carboxylesterase (CES), epoxide hydrolase (EPHX), microsomal GST (MGST), prostaglandin reductase
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(PTGR) and UDP-glucuronosyltransferase (UGT), as well as ATP-binding cassette (ABC) drug-efflux
pumps, are regulated by the CNC-bZIP transcription factor [22]. Around the same time, it emerged
that NRF2 also controls genes encoding antioxidant proteins such as glutamate-cysteine ligase catalytic
(GCLC) and modifier (GCLM) subunits, glutathione peroxidase 2 (GPX2), peroxiredoxin (PRDX1),
cystine/glutamate antiporter xCT (SLC7A11), thioredoxin 1 (TXN1), thioredoxin reductase 1 (TXNRD1)
and sulfiredoxin (SRXN1) [16,22–25]. In a similar vein, NRF2 also regulates genes for proteins involved
in iron and heme metabolism, such as the ferritin heavy (FTH1) and light (FTL1) subunits, the iron
transporter ferroportin (FPN1), biliverdin reductase B (BLVRB) and heme oxygenase 1 (HMOX1),
and so likely limits the generation of reactive oxygen species (ROS) by Fenton chemistry [26,27].
In addition, NRF2-target genes include those encoding enzymes that generate NADPH, such as
glucose-6-phosphate dehydrogenase (G6PD), isocitrate dehydrogenase 1 (IDH1), malic enzyme 1 (ME1)
and 6-phosphogluconate dehydrogenase (PGD), and so supply reducing equivalents that allow oxidized
glutathione and thioredoxin to be reduced and so maintain their antioxidant capacity [24,28–30]; of note,
G6PD and PGD form part of the oxidative arm of the pentose phosphate pathway (PPP), whilst the
non-oxidative arm includes transketolase (TKT) and transaldolase (TALDO1), both of which are also
regulated by NRF2, though induction of these genes was shown by Hozumi Motohashi and colleagues
to predicate on activation of growth factor signalling [31]. Because of its involvement in stress-inducible
GSH and TXN1 synthesis and NADPH generation, these findings suggest NRF2 serves to maintain
antioxidant capacity of cells. Consistent with this notion, it has been reported that in Nrf2-ko mouse
embryonic fibroblasts (MEFs), the level of reduced glutathione (GSH) is only about 30% of that in
wildtype MEFs, and that whilst treatment with the isothiocyanate SFN rapidly depletes intracellular
GSH in both MEF lines, the ability of Nrf2-ko MEFs to regenerate GSH as an adaptive response to
oxidative stress is severely impaired [32].
Besides its role in regulating detoxification and antioxidant genes, NRF2 controls expression of
the scavenger receptors cluster of differentiation 36 (CD36) and macrophage receptor with collagenous
structure (MARCO), which is consistent with it fulfilling a broadly protective role [33,34]. Additionally,
Tom Kensler and colleagues discovered early on that NRF2 controls the expression of proteasome
subunit (PSM) type A, B and C polypeptides associated with protein turn-over [22], and it is now also
recognised to control many components of the autophagy system [35,36]. In addition, NRF2 controls
the expression of various transcription factors, including the aryl hydrocarbon receptor (AHR),
activating transcription factor (ATF) 3, ATF4, CCAAT/enhancer-binding protein beta (CEBPB), MafG,
peroxisome proliferator-activated gamma (PPARγ, or PPARG), peroxisome proliferator-activated
gamma coactivator 1β (PPARGC1B) and retinoid X receptor alpha (RXRα, or NR2B1) [37–39]. NRF2 also
controls its own expression as well as that of its repressor KEAP1 [39].
Activation of NRF2 allows cross-talk with a number of signalling processes. These include
Ca2+-signalling by regulation of the gene encoding transient receptor potential cation channel,
subfamily A, member 1 (TRPA1), resulting in triggering of pro-survival pathways [40]. NRF2 also
cross-talks in a bidirectional fashion with Notch signalling [41]. Moreover, NRF2 has been reported to
influence hedgehog signalling in both a positive [42] and negative [43] manner. Table 1 provides a list
of genes regulated by NRF2.
Table 1. NRF2-target genes.
Function Gene
Phase I drug oxidation, reduction
and hydrolysis
AKR1B10, AKR1C1, AKR1C2, AKR1C3, ALDH1A1, ALDH3A1,
ALDH7A1, CBR1, CES1G, CES1H, EPHX1, NQO1, PTGR1
Phase II drug conjugation * GSTA1, GSTA3, GSTM1, GSTP1, MGST1, SULT1A1, UGT1A1,UGT1A6, UGT2B7
Phase III drug efflux ABCB6, ABCC1, ABCC2, ABCC3
Scavenging of H2O2 CAT, GPX2, GPX4, PRDX1, PRDX6
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Table 1. Cont.
Function Gene
Iron/heme metabolism BLVRB, FECH, FPN1 (also called SLC40A1), FTH1, FTL1,HMOX1
Contribution to maintenance of the
GSH-based antioxidant system GCLC, GCLM, GGT1, GSR1, SLC7A11
Contribution to maintenance of the
TXN1-based antioxidant system TXN1, TXNRD1, SRXN1
NADPH generation to provide
reducing equivalents for GSH and
TXN1 systems
G6PD, PGD, IDH1, ME1
Non-oxidative arm of the pentose
phosphate pathway ** TALDO1, TKT
Import of fatty acids CD36
Scavenger receptor MARCO
Proteasomal subunits
PSMA1, PSMA4, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4,
PSMB5, PSMB6, PSMC1, PSMC3, PSMD1, PSMD5, PSMD7,
PSMD11, PSMD12, PSMD13, PSME1 (encoding PA28αβ)
Autophagy-related proteins SQSTM1 (encoding p62), CALCOCO2, ULK1, ATG2, ATG5,ATG7, GABARAPL1, LAMP2
Transcription factors and associated
factors
AHR, ATF3, ATF4, CEBPB (encoding C/EBPβ), MAFG, PPARG
(encoding PPARγ, or NR1C3), PPARGC1B, RXRA
(encoding RXRα, or NR2B1)
Ubiquitin ligase substrate adaptor KEAP1
Positive regulation of response to
oxidative stress NFE2L2
Activation of Ca+2 channel signalling TRPA1
Activation of Notch signalling NOTCH1
Attenuation of hedgehog signalling
*** PTCH1
* cytosolic glutathione S-transferase (GSTs) induced in rat and mouse, and not the human; ** requires growth factor
signaling; *** both positive and negative control have been reported.
2. Historical Perspective on NRF2 and Cancer Chemoprevention
During early characterisation of the Nrf2-ko mouse, many small molecules that were found to
require the CNC-bZIP transcription factor in order to induce Nqo1 and Gsta1 genes had already been
classed as cancer chemopreventive ‘blocking’ agents because they can prevent or retard the initiation
of carcinogenesis in rodents if administered prior to treatment with a chemical carcinogen [44]. In a
seminal review written in 1966 on agents that can inhibit chemical carcinogenesis [45], the origins of
chemoprevention were traced back to the pioneering work of Isaac Berenblum and colleagues who
published a series of papers from 1929 onwards showing that low doses of dichloroethyl sulphide
(mustard gas) could protect against skin tumourigenesis produced by topical application of tar
to mice [46,47]. Since mustard gas is highly toxic and the demonstration of its effects limited to
skin-painting experiments, these findings were of limited public health relevance as they could not
be applied to humans. Subsequently, Herbert Crabtree reported that a range of relatively innocuous
compounds could protect against skin carcinogenesis caused by 3,4-benzo[a]pyrene [48,49] and,
most intriguingly, linked the ability of these agents to inhibit induction of tumours to alterations in
sulfur metabolism [48]. The notion that chemoprevention extended beyond skin cancer, and could not,
therefore, be simply attributed to physical shielding against absorption of the carcinogen across the skin,
was revealed by several research groups, including that of Elizabeth and James Miller, who showed
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that administration of a low dose of various polycyclic aromatic hydrocarbons protects against liver
carcinogenesis initiated by 3-methyl-4-dimethylaminoazobenzene or 2-acetylaminofluorene [50–52],
results that indicated chemopreventive agents exerted systemic effects.
As chemical carcinogens typically have to be catalytically converted to an unstable reactive
electrophilic intermediate in order to exert their mutagenic and carcinogenic effects [53], in the
case of polycyclic aromatic hydrocarbons by forming an epoxide [54,55], the laboratory of Lee
Wattenberg investigated whether chemopreventive agents might alter drug metabolism in target
organs and so decrease the formation of electrophilic ultimate carcinogens. For example, these workers
showed that treatment of rats and mice with various flavones could increase the hydroxylase activity
of phase I cytochrome P450 (CYP) enzymes towards benzo[a]pyrene in liver and lung, and that
pre-treatment of A/HeJ mice with β-naphthoflavone, and to a lesser extent quercetin, before p.o.
administration of benzo[a]pyrene greatly diminished the number of lung tumours subsequently
observed at autopsy [56,57]. Later, oltipraz was reported to protect against lung tumourigenesis
initiated by various carcinogens including benzo[a]pyrene, diethylnitrosamine and uracil mustard [58].
The potential therapeutic value of chemoprevention received a major credibility boost
with the discovery that synthetic antioxidants such as BHA, butylated hydroxytoluene (BHT)
and ethoxyquin inhibited forestomach carcinogenesis in the mouse initiated by benzo[a]pyrene
or 7,12-dimethylbenz[a]anthracene (DMBA) [59], and that BHT inhibited liver and mammary
carcinogenesis in the rat initiated by 2-acetylaminofluorene [60], principally because BHA and BHT
are encountered as food preservatives [61]. Moreover, benzyl isothiocyanate, indoles, coumarins and
α-angelicalactone, which are also commonly found in the human diet, were also found to inhibit
chemical carcinogenesis [62,63].
With the finding that synthetic antioxidants can protect against carcinogenesis in a range of tissues,
came the realisation that they can induce enzymes that catalyse phase I drug-oxidation/reduction
reactions as well as phase II drug-conjugation reactions. Indeed, it was discovered that chemopreventive
agents augment the activities of EPXH1, NQO1 and AKR isoenzymes as well as GST and UGT
isoenzymes in various tissues [64–71]. Importantly, the increase in GST activity stimulated by BHA
was shown to result from an increase in abundance in mRNA for the GST subunits, rather than
merely an increase in catalytic activity [72,73], and this is true too for the increases in EPXH1, NQO1,
AKRs and UGTs. In the case of benzo[a]pyrene, it is activated by CYP1A1 and CYP1B1 to the ultimate
carcinogen 7β,8α-dihydroxy-9α,10α-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene, which in rodents that
have been fed a diet containing BHA is principally inactivated by EPXH1 and UGT isoenzymes [74],
with GST-catalysed conjugation of GSH with the benzo[a]pyrene diol epoxide playing a relatively
minor role [75] (Figure 2A). It should be noted also that work in human lung cell lines suggests that
AKR isoenzymes participate in the metabolic activation of benzo[a]pyrene [76].
Cancer chemopreventive agents provide protection against exposure to naturally occurring
carcinogens, with a good example being provided by aflatoxin B1 (AFB1), produced by the fungus
Aspergillus flavus, which is a potent hepatocarcinogen but displays selective species toxicity [77]; rats are
relatively sensitive to AFB1 toxicity, whereas mice are resistant. Treating rats with ethoxyquin or oltipraz
was found to protect against AFB1-initiated hepatocarcinogenesis [78,79]. In this case, protection
against the mycotoxin is attributed to induction of genes encoding GSTA5 (originally called Yc2),
a class Alpha GST subunit that in the dimeric enzyme conjugates the genotoxic AFB1 exo-8,9-epoxide
with GSH, and AKR7A1 (originally called AFAR), which catalyses NADPH-dependent reduction of
the cytotoxic AFB1-dialdehyde to an AFB1-dialcohol [80–86] (Figure 2B). Interestingly, mouse liver
constitutively expresses high levels of GST A3-3 (previously called a YcYc homodimer), which has
high activity towards AFB1 exo-8,9-epoxide and is thought to be responsible for the intrinsic resistance
of the mouse to AFB1 hepatocarcinogenesis [87]. Indeed, knockout of Gsta3 renders mice sensitive to
the hepatotoxic effects of the mycotoxin [88].
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3. Global Knockout of NRF2 in the Mouse Results in Diminished Intrinsic Resistance to
Chemical Carcinogenesis and Impairs the Efficacy of Cancer Chemoprevention
As described above, small molecules that inhibit the initiation of carcinogenesis have been
designated cancer chemopreventive ‘blocking’ agents, whereas those that inhibit the later post-initiation
stages of cancer have been called ‘suppressing’ agents [44]. Following the discovery that NRF2 regulates
both the basal and inducible expression of genes encoding drug-metabolising enzymes capable
of detoxifying carcinogenic xenobiotics, various research groups investigated whether loss of the
CNC-bZIP transcription factor might sensitise mice to tumourigenesis and diminish the effectiveness of
chemopreventive agents in gastric, bladder, skin, gastrointestinal tract, oral, mammary, lung and liver
cancer. Such studies revealed that Nrf2-ko mice are more sensitive to DNA damage caused by various
genotoxic compounds, such as benzo[a]pyrene, than wildtype mice [89]. Moreover, knockout of NRF2
in the rat renders them more sensitive to formation of AFB1-N7-guanine DNA adducts in the liver
when exposed to the mycotoxin [90].
The first chemoprevention study to focus on Nrf2-ko mice revealed that whilst 48 h pre-treatment
of the mutant mice with oltipraz could decrease the number of benzo[a]pyrene-initiated forestomach
neoplastic lesions by approx. 55%, oltipraz did not decrease tumour numbers in Nrf2-ko mice [17].
Furthermore, benzo[a]pyrene produced a higher tumour burden in the forestomach of Nrf2-ko mice
than in wildtype mice. A similar loss of chemoprevention in Nrf2-ko mice was found against
benzo[a]pyrene-initiated forestomach cancer using SFN [19].
In a subsequent study of bladder chemoprevention in Nrf2-ko mice, which used N-butyl-N-
(4-hydroxybutyl)nitrosamine (BBN) in the drinking water to initiate carcinogenesis, it was found that
feeding wildtype mice an oltipraz-containing diet a week before exposing them to BBN for 8 weeks,
with oltipraz treatment for the duration of the experiment, reduced the incidence of urinary bladder
cancer to approx. 50% in wildtype mice, but this protection was not afforded to Nrf2-ko mice treated in
an identical manner [91]. Interestingly, the incidence of BBN-initiated bladder cancer was significantly
higher in Nrf2-ko mice than age-matched wildtype mice. Moreover, the Nrf2-mediated protection
against bladder cancer was attributed to increased metabolism of BBN by Ugt1a6.
Later, in a murine skin cancer model that employed a single dose of DMBA followed by repeated
applications over a 25-week period of the tumour promoter 12-O-tetradecanoylphorbol-13-acetate
(TPA), Nrf2-ko mice developed more tumours than their wildtype counterparts and continuous topical
application of SFN that was started prior to DMBA treatment did not diminish tumour numbers,
whilst in wildtype mice SFN treatment decreased the incidence of tumours and the numbers per mouse
over the duration of the experiment [92]. Importantly, this observation suggested that activation of Nrf2
results in a blunting of both the initiation and promotion stages of tumourigenesis [92], and is further
supported by studies employing ultraviolet radiation (UVR) as a complete carcinogen, using either
pure SFN [93], or broccoli extracts as a source of SFN [94] or its biogenic precursor glucoraphanin [95];
it should, however, be noted that in the studies of the effects of SFN on UVR tumourigenesis the
dependence of SFN on Nrf2 has not been investigated.
In colon cancer, the possibility that pharmacological activation of NRF2 protects against
tumourigenesis has been investigated using a colitis-associated carcinogenesis model that involved
administration of a single dose of azoxymethane (AOM) followed by exposure for 10 weeks to dextran
sulfate sodium (DSS). Utilizing this regimen, pre-treatment with the Nrf2 activator cinnamaldehyde
one week before the administration of AOM, and thereafter maintained throughout DSS exposure,
resulted in the number of colon tumours being reduced to approx. 50% in wildtype mice but no such
reduction was observed in Nrf2-ko mice [96]. Interestingly, these workers did not report a higher
incidence of tumours in Nrf2-ko mice when compared with wildtype mice.
In a model of oral carcinogenesis that involved provision of drinking water containing
4-nitroquinoline 1-oxide (4NQO) for 16 weeks followed by ordinary drinking water for 8 weeks, it was
found that topical application of SFN to the tongue three times per week throughout the experiment
decreased oral carcinogenesis to about 63% in wildtype mice [97]. By contrast, these workers found that
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SFN provided no protection against oral carcinogenesis in Nrf2-ko mice [97]. Interestingly, Nrf2-ko mice
are more sensitive to 4NQO-initiated carcinogenesis than wildtype mice [98].
Chemoprevention of DMBA-induced mammary cancer in rats has been reported using various
blocking agents that are known to activate Nrf2, including SFN [99], and although an NRF2-ko rat is
available it is currently not known if such protection is abolished in the mutant animal. Nrf2-ko mice
have been found to be more sensitive to DMBA-induced mammary cancer than their wildtype
counterparts [100], but little has been reported about the ability of chemopreventive agents to protect
against mammary tumourigenesis in Nrf2-ko animals.
Early experiments into chemoprevention of lung cancer indicated that β-naphthoflavone and
oltipraz can protect against initiation of tumourigenesis by benzo[a]pyrene, diethylnitrosamine and
uracil mustard [57,58] but it is not known if this can be attributed to activation of Nrf2. More recent
experiments have shown that the flavone chrysin, when administered to mice either before or 4 weeks
after treatment with benzo[a]pyrene diminished histopathology markers of lung cancer, but again
it is not known if this protection was mediated by Nrf2 [101]. Furthermore, a curcumin-related
compound called bis[2-hydroxybenzylidene]acetone (BHBA) has been shown to protect female
A/J mice against the formation of lung adenocarcinoma when given for two weeks prior to the
administration of vinyl carbamate, but even though BHBA was shown to induce ARE-driven luciferase
activity, it remains uncertain whether in this instance chemoprevention is mediated by Nrf2 [102].
Using an ethyl carbamate-induced lung carcinogenesis model, Nrf2-ko mice have been shown to be
substantially more sensitive than wildtype mice to the early stages of tumourigenesis but, surprisingly,
seem to be more resistant to the later stages of lung tumourigenesis than their wildtype counterparts,
suggesting that whilst Nrf2-target genes antagonise initiation of chemical carcinogenesis they facilitate
the later transformation of benign adenoma to adenocarcinoma that may entail mutation of Kras [103].
Interestingly, the vinyl carbamate-initiated lung adenocarcinomas in Nrf2-ko mice were found to be
larger than those in wildtype mice and were characterized by infiltration of tumour-promoting immune
cells as evidenced by overexpression of genes for cytokines and antigen presentation, including Csf1,
Cxcl1, Cxcl12 and Ccl9 [104]. Support for the notion that Nrf2 differentially influences the various stages
of carcinogenesis has come from the fact genetic activation of Nrf2, using the Keap1-floxed hypomorph
(i.e., Keap1-knockdown or Keap1FA/FA) mouse, protects mice against tumourigenesis, probably by
upregulating genes encoding enzymes that detoxify the ultimate carcinogen vinyl carbamate epoxide,
but that the tumours obtained from the Keap1FA/FA mice grew more robustly when transplanted into
nude mice than those from Keap1+/+ mice [105]. Consistent with this proposal, in KrasLSL-G12D/+ mice,
which harbour oncogenic Kras, pharmacological upregulation of Nrf2 by treatment with SFN after
lung tumourigenesis had been initiated has been found to result in a modest 1.35-fold increase in the
number of tumours observed on the surface of the lungs [106], though it should be noted that this is
possibly controversial as prolonged treatment with SFN has also been reported not to increase cancer
in Kras-based models of lung tumourigenesis [107].
The study of chemoprevention of liver cancer has been complicated by the fact that
the classic hepatocarcinogen AFB1 displays marked species selectivity: the rat is sensitive to
AFB1-hepatocarcinogenesis and can be protected by chemopreventive blocking agents, whereas the
mouse is resistant. NRF2-null rats are highly sensitive to the genotoxic effects of AFB1 and have
been found to die of liver cirrhosis rather than develop hepatomas (Dr Keiko Taguchi and Professor
Masi Yamamoto, personal communication). Hepatocarcinogenesis can be studied in the mouse using
CCl4, DMBA or diethylnitrosamine (DEN). Nrf2-ko mice are substantially more sensitive to CCl4
than wildtype mice, and pharmacological or genetic activation of the CNC-bZIP transcription factor
can protect against toxicity [108,109]. Little has been reported about the effect of Nrf2 on the toxic
effects of DMBA in mouse liver. However, rather surprisingly, it has been found that in the mouse,
Nrf2 upregulation resulting from somatic mutation in the Nfe2l2 gene is necessary for DEN-induced
liver carcinogenesis, and thus Nrf2-ko mice are resistant to the carcinogenic effects of DEN [110].
Cancers 2020, 12, 3609 10 of 48
Whilst not documented, it seems probable that tissues in which Nrf2-ko mice are more sensitive
than wildtype mice to chemical carcinogenesis reflect the extent to which the CNC-bZIP transcription
factor controls the basal expression of drug-metabolising enzymes that detoxify the chemical carcinogen
employed to initiate cancer. These intrinsic variables may in turn be influenced by environmental
factors such as diet. Similarly, the robustness of chemoprevention will likely depend on the degree
to which Nrf2 can increase the activity of detoxification enzymes and the duration of this increase in
activity. Besides these pharmacology-associated variations in the host, once initiated, the premalignant
adenomas, adenocarcinomas and malignant cells will exert a wide range of host-tumour cell variations
that will reflect the types of somatic mutations they have acquired during evolution of the tumour.
Presumably, these variations reflect the tumour type and the environment in which they arise.
4. Cancer Chemopreventive Blocking Agents Possess Thiol Reactivity
Up until the discoveries of NRF2 and KEAP1, the mechanism by which cancer chemopreventive
agents induce gene expression was the subject of considerable conjecture. For example, as AHR-mediated
induction of CYP1A1 by polycyclic aromatic hydrocarbons provided the earliest paradigm for the
regulation of drug-metabolising genes by xenobiotics, some thought it was likely that ligand binding
to a receptor would be necessary for chemopreventive agents to induce genes encoding GSTs and
NQO1. However, Paul Talalay and colleagues pointed out that whilst the anti-cancer compounds that
induce Nqo1 in murine Hepa1c1c7 cells varied enormously in structure, they were all Michael reaction
acceptors and thus electrophilic in nature, and proposed that this was the trigger for induction of
Nqo1, rather than some receptor-defined stereochemical property [111,112]. Besides Michael acceptors,
these workers later identified a diverse range of inducing agents with electrophilic properties including
diphenols, phenylenediamines, quinones, dithiolethiones, isothiocyanates, H2O2, hydroperoxides,
mercaptans, trivalent arsenicals and heavy metals that activated ARE-driven gene expression [113].
Because of their ability to react with nucleophilic sulfhydryl groups, many chemopreventive agents
can form conjugates with GSH and would be capable of modifying thiol groups in proteins [114,115],
and many of these agents were found to be substrates for GST [116,117]. As chemopreventive agents
increase the abundance of enzymes that detoxify electrophiles, along with levels of GSH, the mode of
adaptation they elicited was dubbed the ‘electrophile counterattack response’ [118].
5. Repression of NRF2 by KEAP1 Requires Two Binding Motifs in the Transcription Factor
Identification of KEAP1 as a protein that binds the N-terminal NRF2-ECH homology (Neh)
2 domain of NRF2, and inhibits basal and inducible ARE-driven gene transcription, represented a
milestone in the chemoprevention field [119]: NRF2 contains seven domains, Neh1-Neh7 (Figure 3).
Crucially, KEAP1 binds NRF2 through its Kelch-repeat domain [120], and as it is a dimeric protein
it contains two NRF2-binding sites [121,122]. KEAP1 contains five domains, namely, an N-terminal
region (NTR), a Broadcomplex, Tramtrack, Bric-à-brac (BTB) dimerization domain, an intervening
region (IVR) a six-bladed Kelch-repeat domain, and a C-terminal region (CTR). Notably, two separate
amino acid sequences within the Neh2 domain of NRF2 can bind to the KEAP1 dimer, called DLG
and ETGE motifs (representing amino acids 29–31 and 79–82, respectively), with the ETGE motif
possessing a much greater affinity for the Kelch-repeat domain of KEAP1 than the DLG motif [121,123].
It has subsequently been recognised that amino acids 23–36 around the DLG motif and amino acids 78
and 83 flanking the ETGE motif also contribute to the interaction with the Kelch-repeat domain of
KEAP1 [124]. The existence of a low-affinity and a high-affinity binding site in NRF2 for KEAP1 results
in a ‘two-site substrate recognition’ or ‘hinge and latch’ mechanism where the simultaneous docking
of NRF2 onto the KEAP1 dimer through both of its DLG and ETGE motifs is required for repression of
the CNC-bZIP transcription factor by KEAP1.
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Following discovery of KEAP1, various hypotheses were proposed about how it might regulate
NRF2 with cytoplasmic sequestration and phosphorylation allowing release of the transcription
factor from KEAP1 and nuclear translocation, which has attracted uch attention [revie ed in [125]].
These were, however, largely abandoned when it was recognised that KEAP1 is responsible for
targeting NRF2 for rapid proteasomal degradation and that this ability is impaired by chemopreventive
agents such as SFN [126]. Subsequently, it was demonstrated by various research groups that KEAP1
acts as a substrate adaptor for the CUL3 E3 ubiquitin ligase complex, called CRLKEAP1 [127–130].
CUL3 is a member of a conserved family that serve as scaffold proteins and allow the formation of a
multi-subunit complex that contains an E2 ubiquitin-conjugating enzyme [131]. As shown in Figure 3,
CUL3 contains three cullin repeat (CR1, CR2 and CR3) domains, a cullin homology (CH) domain,
and a C-terminal neddylation site.
The prevailing view is that both the DLG and ETGE motifs of NRF2 must engage with the two
Kelch-repeat domains in dimeric KEAP1 for the CNC-bZIP transcription factor to be ubiquitylated,
and that chemopreventive agents and oxidative stressors readily perturb binding of NRF2 to KEAP1
by the low-affinity DLG motif, and so prevent both of the two-site interactions from being formed
correctly. This, in turn, causes a logjam in the ubiquitylation pathway that allows newly translated
NRF2 to bypass the CRLKEAP1 co plex and translocate uni peded to the nucleus here it dimerises
with small MAF proteins to transactivate ARE-driven genes [132,133].
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6. The Triggering of Multiple Thiol-Based Sensors in KEAP1 by Thiol-Reactive Small Molecules
Results in De-repression of NRF2 and Protection against Oxidative Stress
Mouse and human KEAP1 comprise 624 amino acids, and amongst these residues the murine and
human proteins contain 25 and 27 cysteine (Cys) residues, respectively. Recognition that roughly half
of the Cys residues in mammalian KEAP1 proteins are positioned in close proximity to basic amino
acids, suggested to a number of researchers that the -SH group of such residues would exist in a thiolate
anion form (-S−) and so would react readily with soft electrophiles, making KEAP1 a strong candidate
as the sensor of chemopreventive agents that stimulate NRF2-mediated gene induction. According to
this proposal, it was envisioned that modification of certain Cys residues in KEAP1 would prevent
it from allowing CRLKEAP1-directed ubiquitylation of NRF2. Once modified, KEAP1 is likely to be
cleared from the cell by autophagy [134], and presumably any associated NRF2 that is bound just via
its ETGE motif will be degraded in the same way [135].
Consistent with the idea that chemopreventive agents act as thiol-active reagents, Cys257, Cys273,
Cys288 and Cys297 in purified recombinant mouse Keap1 were found to be modified by the inducer
dexamethasone 21-mesylate [136]. Confirmation that Cys273 and Cys288 in Keap1 are required to
suppress ARE-driven luciferase activity ex vivo was obtained by ectopic expression of wildtype and
mutant forms of the adaptor protein in Keap1-ko embryonic fibroblasts [137]. Besides the requirement
for Cys273 and Cys288 in KEAP1 to allow repression of NRF2, Cys151 in KEAP1 was found to
be essential for the inducer SFN and the BHA metabolite tert-butyl hydroquinone (tBHQ) to block
ubiquitylation of NRF2 by CUL3 [129], and residues Cys226 and Cys613 were found to be necessary
for activation of NRF2 by Cd2+, As3+, Se4+ and Zn2+ [138] and by H2S [139]. More recently, it has been
reported that Cys226, Cys613, Cys622 and Cys624 are engaged in the sensing of H2O2, through the
formation of disulfide bonds between these residues [140]. Interestingly, there is redundancy in
the system insofar as mutation of one of these four Cys residues still allows the mutant KEAP1 to
sense H2O2 [140]. In view of the facts that the inherent reactivity of the Cys thiols in PRDX1 and
PRDX2 are much higher than those in most proteins and that these enzymes are very abundant in the
cell [141], an important possibility is that these thiol peroxidases act as the initial receptor for H2O2
and, following the formation of a disulfide bond within PRDX1 or PRDX2, relay this information to
KEAP1 via the formation of mixed disulphide bonds (Figure 4). This would proceed via the formation
of a disulfide exchange intermediate between PRDX1/2 and KEAP1, that would lead to PRDX1 and/or
PRDX2 being reduced and KEAP1 oxidised, with the oxidised KEAP1 being ultimately reduced by the
TXN1/TXNRD1 couple. Notably, this type of PRDX1/2-based redox relay system has been reported
for apoptosis signalling kinase 1 (ASK1) and signal transducer, activator of transcription 3 (STAT3)
and DJ-1 [142–144], and may also hold true for KEAP1. Whilst KEAP1 is widely recognised to contain
reactive Cys residues, it is substantially less abundant than PRDX1 or PRDX2, and so how a H2O2
redox signal penetrates the antioxidant defence to be perceived by KEAP1 is unclear.
From research stimulated by an interest in chemoprevention, a picture has emerged of KEAP1
as a ubiquitin ligase substrate adaptor that allows cellular adaptation to a variety of redox stressors
through complex thiol-based modifications to its various reactive Cys residues that alter its ability
to repress NRF2. An interesting feature to emerge is that the Cys-based sensors in KEAP1 recognise
different electrophilic agents, but this remains incompletely understood. Just how KEAP1 cross-talks
with other components of redox signalling pathways, such as PRDXs, is not understood.
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7. NRF2 is Frequently Upregulated in Malignant Disease
Over many years, studies of expression of detoxification enzymes in preneoplastic rat hepatocyte
nod les, human tumour and drug-resistant cancer cell lines have provid d compelling evidence
that GSH, glutathion -biosynthetic nzymes, GSTs, UGTs, NQO1, EPHX1 and AKRs are fr quently
overexpr ssed in maligna t cells and that thi is often associated with resistance to chemotherapeutic
agents [71,80,145–149]. With the benefit of hindsight, these finding should have led researchers to
anticipate that NRF2 was likely to be commonly upregulated during tumourigenesis. However,
the literatu indicating that NRF2 mediates chemoprevention seemed at odds with such an
interpretation. Evidence that repression of NRF2 by KEAP1 is impaired in human cancer came
initially from the laboratory of Shyam Biswal through the demonstration that the KEAP1 gene is subject
to somatic mutations in some cell lines and clinical samples from patients with non-small cell lung
cancer (NSCLC) [150]. In particular, these researchers identified mutations in KEAP1 that occurred
throughout regions encoding the BTB, IVR and Kelch-repeat domains, findings that were confirmed
and extended by others [151]. Shortly thereafter, it was discovered that somatic mutations in NFE2L2
commonly occur in NSCLC and oral cancer cell lines as well as various primary lung cancers and
primary head and neck cancers, and that the somatic mutations resulted in amino acid substitutions at
residues associated with the DLG and ETGE motifs in NRF2 [152].
Examination of second-generation sequencing of a large number of tumours deposited in the
catalogue of somatic mutations in cancer (COSMIC) and the cancer genome atlas (TCGA) databases
revealed that NFE2L2 and KEAP1 are mutated in various common cancers, including lung, head and
neck, and bladder [153–159] (see Table 2). It has also been noted that intragenic deletions occur in
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NFE2L2 resulting in translation of NRF2 isoforms that lack amino acids that interact with KEAP1 in
patients with squamous NSCLC and head and neck carcinoma [160]. Based on the facts that the somatic
mutations in NFE2L2 are restricted to regions of the gene encoding the DLG and ETGE motifs and their
flanking amino acids, that such ‘hot spot’ mutations are presumed to result in gain-of-function in NRF2,
and that NFE2L2 is sometimes amplified, NRF2 has been designated an oncogene [161]. Using a variety
of computational bioinformatic tools NFE2L2 mutations have been considered likely to drive lung,
oesophageal, cervical, bladder and uterine cancers, though this has not been formally tested [162,163].
As shown in Figure 5, NRF2 can also be upregulated by oncogene-stimulated transactivation of NFE2L2,
as demonstrated for Kras, Braf and Myc [164].
Table 2. Frequency of mutations in KEAP1, NFE2L2 and CUL3 across different cancer types.
Cancer Type Percentage of Somatic Mutation Reference Samples Analysed
KEAP1 NFE2L2 CUL3
Lung 14.2% 7.3% 3.4% [153]
Whole-exome sequencing of 660
LUAD and 484 LUSC
tumour/normal pairs
Oesophageal 3.4% 4.5% 1.1% [154]
Whole-genome or whole-exon
sequencing of 88 ESCC
tumour/normal pairs
Liver 5.1% 4.0% 0% [155] Hepatocellular carcinomas 369and 3 fibrolamellar carcinoma
Head and neck 4.3% 6.1% 3.6% [156]
Whole exome sequencing and/or
whole genome sequencing of 279
head and neck squamous cell
carcinoma tumour/normal pairs
Gastric 3.1% 0.3% 2.0% [157]
Whole exome sequencing of 295
primary gastric adenocarcinomas
tumours with matched normal
Bladder 3.1% 8.7% 0% [158]
Whole exome sequencing of 131
high grade muscle invasive
urothelial bladder carcinomas
Colorectal 1.4% 0.9% 0% [159]
Whole exome sequencing in 224
of the 276 colorectal carcinoma
tumour/normal pairs
This table was created using Cbioportal [165,166].
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Figure 5. Mechanisms of upregulation of NRF2 in tumours. The cartoon shows the various ways in
which NRF2 activity can be upregulated in cancer. The top left-hand panel shows how NRF2 activity
can be increased by oncogenic proteins: the middle top panel shows how p62/SQSTM1 binds to KEAP1,
thereby preventing KEAP1 from repressing NRF2; the top right-hand panel indicates how microRNAs
can increase NRF2 activity through interacting with either NFE2L2 or KEAP1 transcripts. The center
panel illustrates regions of KEAP1 and NFE2L2 that are frequently somatically mutated in cancer
(with mutations represented by red circles). The bottom left-hand panel depicts how NRF2 abundance
can be enhanced by increases in NFE2L2 copy number or decreases in KEAP1 copy number; the bottom
center panel depicts how interaction with ROS oxidize cysteine residues in KEAP1 preventing it from
targeting NRF2 for proteasomal degradation; the bottom right-hand panel highlights how epigenetic
alterations in KEAP1 and NFE2L2 impact NRF2 abundance.
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As somatic mutations in KEAP1 occur across the entire gene and cause loss-of-function, it has
been referred to as a tumour suppressor [161], and it has been proposed to drive cancers of the lung,
head and neck, and liver [162,163]. Besides somatic mutations, KEAP1 is also sometimes subject to
intragenic deletions or its expression suppressed by hypermethylation or by micro-RNAs [167–169].
Loss of SWI/SNF chromatin-remodeling complex activity also increases NRF2 activity [170]. Moreover,
the ability of KEAP1 to repress NRF2 can be inhibited by oncometabolites such as fumarate [171,172],
methylglyoxal [173] and succinylacetone [174], or NRF2 can be upregulated by overexpression of
proteins that contain ETGE, or ETGE-like, motifs resulting in NRF2 being out-competed for binding
to KEAP1; examples include iASPP, CHD6, DPP3, FAM129B, IKKβ, LAMA1, MCM3, SQSTM1/p62,
PALB2, PGAM5 and WTX [175].
Although no mutations in KEAP1 or NFE2L2 have been reported in tumours of the central
nervous system [155], NRF2 is hyperactivated in a subset of glioma patients, whose tumours display
a mesenchymal subtype [176]. Evidence suggests a positive feedback loop between p62/SQSTM1
and NRF2 is responsible for NRF2 upregulation. Of interest, NRF2 has also been shown to facilitate
glioma development by inducing expression of the transcriptional co-activator TAZ, a component of
the Hippo signalling pathway [177]. Upregulation of NRF2 in glioma cells accelerates proliferation and
oncogenic transformation, and protects against ferroptosis [178]. Additionally, IDH1-mutant glioma
cells are dependent on NRF2-target genes to scavenge ROS [179].
8. Constitutive Activation of NRF2 Supports Post-Initiation Stages of Cancer
Whilst the designations of NRF2 and KEAP1 as an oncoprotein and a tumour suppressor protein,
respectively, seem appropriate they should be treated with caution as there is no evidence that chronic
activation of NRF2 is sufficient to initiate tumourigenesis. Rather, on its own, chronic activation
of NRF2 can sometimes result in hyperplasia, but not cancer. Thus, modest permanent activation
of Nrf2, as observed in the floxed Keap1FA/FA hypomorphic mouse, in which Keap1 is effectively
constitutively knocked down, provides increased cytoprotection and has not been reported to result
in any obvious long-term susceptibility to tumourigenesis [180]. Global knockout of Keap1 in the
mouse, which provides higher upregulation of Nrf2 than observed in Keap1FA/FA mice, was by contrast,
found to result in severe hyperkeratosis of the oesophagus and forestomach that resulted in postnatal
death from malnutrition within 3 weeks of age, but the Keap1−/− mice showed no signs of malignant
disease [181]. Moreover, liver-specific knockout of Keap1 (e.g., Keap1FA/FA; Alb-Cre mice) has not
been reported to result in hepatocellular carcinoma, despite the animals having been first reported
in 2006 [182]. Furthermore, persistent hyperactivation of NRF2 in human A549 lung cancer cells
results in enhancer remodelling, allowing transcriptional activation of NOTCH3 by an NRF2-CEBPB
complex that strongly supports tumourigenesis, and which is not observed in normal cells under stress
conditions, indicating that continual activation of NRF2 in cancer cells results in overexpression of an
enlarged battery of genes that is distinct from that induced by NRF2 in normal cells [183].
A number of researchers have studied the effect of expressing mutant hyperactive forms of NRF2,
modelled on somatic mutants of NFE2L2 identified in clinical lung cancer samples (e.g., Nrf2E79Q and
Nrf2∆Neh2), and none of these have provided evidence that chronic Nrf2 hyperactivity is sufficient
to initiate tumourigenesis. Thus, generation of a Nfe2l2LSL-E79Q; Krt14-Cre mouse in which Nrf2E79Q
is expressed in keratin 14-positive tissues, revealed that expression of a constitutively active mutant
form of the CNC-bZIP transcription factor resulted in hyperplasia of squamous cell tissue of the
tongue, oesophagus and forestomach, but not squamous cell carcinoma, and that in oesophageal
tissue this was associated with overexpression of well-recognised members of the ARE-gene battery, as
well as genes for growth factors and related factors such as those encoding Areg, Bmp6, Epgn, Ereg,
Hbegf, Myc, Vegfa and Wnt5a [184]. Similarly, hepatocyte-specific expression of Nrf2E79Q resulted in
hepatomegaly that was accompanied by overexpression of Areg and Tgfa, which encode ligands for the
EGFR, and Pdgfc, which encodes a ligand for the PDGFR, but did not result in liver cancer [185]. In a
mouse model in which a constitutively active form of Nrf2 that lacks amino acids 1–88 (i.e., Nrf2∆Neh2,
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called caNrf2) was expressed from the keratin 5 promoter (with the line called K5cre-caNrf2), the mutant
mice developed chloracne-like skin disease with hyperkeratosis of hair follicles in the epidermis [186],
but not cancer. However, when used in skin carcinogenesis experiments, the K5cre-caNrf2 mouse was
found to support survival of keratinocytes that harboured oncogenic mutations. In these experiments,
crossing K5cre-caNrf2 mice with a HPV8-stimulated skin tumourigenesis mouse produced better
survival of oncogene-expressing cells than when a DMBA/TPA two-step chemical carcinogenesis model
was employed [187]. By contrast with these findings, it has been reported that ectopic expression
of caNrf2 in primary breast cancer cells had no significant effect on the rate of primary tumour
formation [188]. Taken together, these different mouse models all suggest that constitutive activation
of Nrf2 is not sufficient to initiate cancer but may support cell growth, though this likely depends on
the oncogene(s) involved.
Expression of Nrf2∆Neh2 in mouse fibroblasts (i.e., in Colα2Cre-caNrf2 mice) was found to elicit a
senescence-associated secretory phenotype with increased expression of cytokines, growth factors and
extracellular matrix proteins that affected neighbouring cells, suggesting it conferred a cancer-associated
fibroblast phenotype [189]. This finding seems at variance with other reports that activation of NRF2
delays senescence in human fibroblasts [190], and may simply reflect the hyperactive nature of
Nrf2∆Neh2 or other context-dependent factors. Interestingly, through use of both floxed Keap1FA/FA
hypomorphic mice and floxed Keap1FB/FB “normal” mice in a KrasLSL-G12D/+ mouse lung cancer model,
Masi Yamamoto and colleagues showed that activation of Nrf2 in the microenvironment surrounding
the tumour restricts progression of lung cancers in which Nrf2 is upregulated, and bone marrow
transplantation experiments revealed that activation of the transcription factor in hematopoietic cells
contributed significantly to suppression of the tumour [191], findings that suggest high NRF2 activity
can suppress the later stages of cancer by supporting immune cell function.
In conclusion, based on studies of the evolution of NSCLC, it seems likely that NRF2 is upregulated
at an early adenocarcinoma stage of disease [192], which accords with data from rat liver preneoplastic
nodules obtained using the Solt-Farber protocol [193,194]. Collectively, these results suggest that
NRF2 upregulation is not a potent cancer driver, and that alone, its constitutive activation cannot
initiate tumourigenesis. Provocatively, upregulation of NRF2 in immune cells seems to combat late
progression and dissemination of malignant disease.
9. Mechanisms by Which Upregulation of NRF2 Supports Post-Initiation Stages of Cancer
Given that hyperactivation of NRF2 is not sufficient to initiate tumourigenesis, it is necessary
to establish why it is upregulated in certain types of cancer. The answer appears to be that NRF2
hyperactivation contributes to tumourigenesis by ameliorating oxidative stress, supporting cell
growth/proliferation by various means (e.g., increasing the PPP, serine synthesis and autophagy) and
attenuating the immune system. Before addressing the question of why NRF2 is upregulated in certain
cancers, it should first be asked whether NRF2 is required for carcinogenesis under conditions where
it is subject to normal homeostatic control. Research into the inhibitory effects of oxidative stress
on tumourigenesis in a murine Kras oncogenic pancreatic cancer model has revealed that Nrf2 is
necessary for Kras-driven pre-invasive pancreatic intraepithelial neoplasia as the number of lesions in
KrasLSL-G12D/+; Nfe2l2−/− mice was much lower than in KrasLSL-G12D/+; Nfe2l2+/+ mice [164]. Moreover,
using Alb-Cre; KrasLSL-G12D/+; p53LSL-R172H/+ mice, deletion of Keap1 has shown that upregulation of
Nrf2 accelerated Kras/p53-driven cholangiocarcinoma [195]. Similarly, using a CRISPR-Cas9 strategy,
deletion of Keap1 has been found to accelerate Kras-driven lung adenocarcinoma [196]. Additionally,
constitutive activation of Nrf2 has been shown to promote lung cancer in a mouse model initiated by
knockout of phosphatase and tensin homolog (Pten) by administering adenoviral Cre to Keap1FB/FB;
PtenF/F mice, with the latter mutation causing permanent activation of protein kinase B (PKB)/Akt [197].
As cancer cells produce high levels of ROS to sustain proliferation, and also have to withstand
oxidative stress during metastasis, it seems likely that upregulation of Nrf2 benefits the tumour because
the resulting overexpression of antioxidant genes prevents ROS-stimulated cell death (reviewed in [8]).
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Besides directing the expression of genes encoding enzymes that scavenge ROS, NRF2 also controls
the expression of PPP genes in both the oxidative (G6PD and PGD) and non-oxidative (TALDO1 and
TKT) arms, and overexpression of these may contribute to survival and proliferation of cancer
cells by increasing synthesis of NADPH and ribonucleotides [198]. Of note, rapidly proliferating
cancer cells primarily use the non-oxidative arm of the PPP to generate ribonucleotides for nucleic
acid biosynthesis [198].
In experimental cancer models, the mechanisms by which Nrf2 upregulation promotes
carcinogenesis have not been rigorously proven, at least they have seldom entailed knockout of
individual Nrf2-target genes. An example of this approach is the tamoxifen-induced conditional
knockout of Slc7a11 in pancreatic ductal adenocarcinoma cells generated in KrasLSL-G12D/+; Tp53R172H/+;
Pdx1FlpOtg/+; Slc7a11Fl/Fl; Rosa26CreERT2/+ mice, experiments in which knockout of Slc7a11 in the tumour
resulted in ferroptotic death of the tumour cells and increased survival [199]. Whilst the above study
focused on the importance for tumour survival of maintaining intracellular cysteine levels to combat
ROS-stimulated death, work with the murine MMTV-PyMT spontaneous mammary cancer model,
crossed onto a Gclm−/− background, along with use of the GCL inhibitor buthionine sulfoximine and the
TXNRD inhibitor auranofin, indicated that the GSH antioxidant system supports early tumourigenesis
and that the TXN system can compensate for depletion of GSH by increasing cystine import via Slc7a11,
inferring a level of redundancy [200]. As Nrf2 controls both GSH- and TXN1-based antioxidant systems,
it is likely a major factor in determining whether cancer cells can withstand oncogene-generated ROS.
In a model of recurrent breast cancer, tumour cells that survived oxidative stress caused by
oncogene inhibition did so by NRF2-directed metabolic reprogramming that entailed overexpression
of genes for oxidative PPP enzymes and TXN1, TXN2 and TXNRD1, but not those for GSH synthesis,
suggesting NRF2 aids formation and growth of recurrent tumours [188]. Importantly, in addition to
NRF2-directed overexpression of antioxidant enzymes, other mechanisms can be utilized to increase
GSH during the later stages of cancer development including, for example, increased generation of
NADPH via the folate pathway during metastasis [201] and activation of mTOR signalling as well as
increased mitochondrial metabolism and glutamine flux stimulated by estrogen-related receptor α
(ERRα) in lapatinib-resistant breast cancer cells [202].
The fact NRF2 regulates metabolic flux through the PPP suggests it is likely to aid tumour
survival and growth by directing NADPH generation and de novo ribonucleotide synthesis [31].
Treatment of KrasLSL-G12D/+; Keap1FB/FB mice (that had already received adenoviral Cre intranasally)
with the PGD inhibitor 6-aminonicotinamide prevented formation of lung adenomas and resulted
in just lung hyperplasia [203], findings that suggest the PPP contributes substantially to the
ability of upregulated Nrf2 to support tumourigenesis, though the extent to which this is due
to increased production of NADPH or ribonucleotides requires clarification. Moreover, as NRF2
regulates ATF4, it indirectly controls serine synthesis by regulating expression of genes encoding
phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase-1 (PSAT1) and serine
hydroxymethyltransferase-2 (SHMT2), and as serine is used as an intermediate in glutathione and
nucleotide production, NRF2 upregulation supports cancer cell growth and proliferation [204].
Besides antioxidant systems and the PPP, NRF2 also regulates expression of proteasome subunits
and components of the autophagy system, and overexpression of these upon upregulation of NRF2
likely also contributes to cancer cell survival and proliferation [205]. Furthermore, autophagy plays
a crucial role in inhibiting tumourigenesis in the liver, presumably by preventing accumulation of
dysfunctional mitochondria and ameliorating oxidative stress, as evidenced by the spontaneous
development of hepatic adenomas in mice with mosaic deletion of Atg5 and hepatocyte-specific
deletion of Atg7 [206]. Once tumours are established however, autophagy often promotes cancer
cell growth by recycling non-essential cellular components to support oxidative phosphorylation
and thereby overcome nutrient stress [207,208]. Intriguingly, inhibition of autophagy, by chloroquine
treatment or knockout of ATG7, in autophagy-dependent cancer cells stimulates adaptation by
NRF2-mediated induction of proteasomal subunit genes, with largest increases observed for PSMB8,
Cancers 2020, 12, 3609 19 of 48
PSMB9, PSMB10 and PSMC1, indicating NRF2-mediated regulatory crosstalk between the proteasome
and autophagy [36].
Obesity-stimulated liver steatosis represents a growing cause of hepatocellular carcinoma, and is
associated with inhibition of autophagy and the accumulation of p62/SQSTM1 [209]. In the liver,
phosphorylation of LC3 (i.e., microtubule-associated proteins 1A/1B light chain 3B) at Ser12 by the
atypical protein kinase C (PKC)λ/ι inhibits autophagy by preventing LC3 from interacting with
p62/SQSTM1 [210]. In mice treated with DEN and fed a high-fat diet, hepatocyte-specific knockout
of PKCλ/ι (in Alb-Cre; PrkciF/F mice) resulted in multiple hepatocellular carcinomas, some of which
were aggressive, whilst similarly treated PrkciF/F mice only developed benign hepatic adenomas [210].
These workers found knockout of PKCλ/ι increased autophagy and ROS levels, causing oxidative stress
and, consequently, activation of Nrf2. They also found hepatocytes from Alb-Cre; PrkciF/F mice exhibited
higher rates of proliferation than controls, and that knockdown of Nrf2 suppressed proliferation in
the PKCλ/ι-knockout hepatocytes. Together, these results indicate Nrf2 is an important component of
the tumour environment when autophagy is increased but they do not give an insight into whether
NRF2-mediated overexpression of autophagy genes contributes to tumourigenesis.
As NRF2 regulates ATF4, it is likely to indirectly control the expression of cyclooxygenase 2
(COX2) and production of prostaglandin E2 (PGE2), which suggests NRF2 upregulation may foster
a microenvironment that allows tumour cells to evade the innate immune system. In melanoma
cells, knockout of NRF2 has been shown to decrease COX2 levels and PGE2 production, and this was
associated with a large increase in expression of innate immune response genes involved in defence
against viral infection, such as Rsad2, Ifih1, Ifit1 and Isg15 [211]. Whilst these findings suggest NRF2
upregulation can suppress innate immune responses, this conclusion should be tempered by the
finding that activation of Nrf2 in the microenvironment surrounding the tumour restricts progression
of lung cancers [191].
Lastly, it is well recognised that NRF2 upregulation is associated with chemoresistance and
radioresistance, due to overexpression of drug-metabolising enzymes and antioxidant systems [205].
The overexpression of drug-metabolising genes caused by hyperactivation of NRF2 is likely to increase
resistance to ferroptosis because AKR isoenzymes catalytically reduce lipid peroxidation products that
trigger ferroptotic cell death [212]. Of note, AKR1C1, AKR1C2 and AKR1C3 are particularly effective
at reducing 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene [213].
10. Evidence of Dysregulation of NRF2 in Human Cancers and Segregation with Activated Oncogenes
10.1. Upregulation of NRF2 in Lung Tumours
Lung cancer is the leading cause of cancer associated mortality world-wide [214], partly due to its
highly heterogenous nature and often late stage of diagnosis. Environmental factors such as exposure
to cigarette smoke, asbestos, radon gas, arsenic and silica have been linked to lung cancer development
and poor outcomes [215,216]. For example, smokers are 10–20 times more likely to develop the disease
than non-smokers [215]. NSCLC is the major histological subtype of lung cancer, representing >80% of
all lung cancer cases [216,217]. NSCLC can be further histologically subdivided, according to tissue of
origin, into adenocarcinoma (LUAD, which is the most prevalent), squamous cell carcinoma (LUSC)
and large cell carcinoma [218]. Molecular profiling of both LUAD and LUSC revealed thirty-eight
genes frequently mutated in LUAD and twenty frequently mutated genes in LUSC, with six commonly
mutated genes in both lung cancer subtypes: these are, TP53, RB1, ARID1A, CDKN2A, PIK3CA and
NF1 [153] (see Table 3 for the frequency of mutations in genes implicated in NRF2 activation in NSCLC).
Due to the few overlapping mutations, it is thought that somatic mutations in driver genes differ in
LUAD and LUSC.
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Table 3. Mutations in genes implicated in regulating NRF2 activity in NSCLC *.
Pan-Lung Cancer
Alteration
Gene Name Number of Samples with theMutation
Number of Samples without the
Mutation
NFE2L2 105 (9%) 1039 (91%)
KEAP1 170 (15%) 974 (85%)
CUL3 51 (5%) 1093 (96%)
KRAS 259 (23%) 885 (77%)
TP53 776 (68%) 368 (32%)
PIK3CA 276(24%) 868 (76%)
PTEN 102 (9%) 1042 (91%)
STK11 118 (10%) 1026 (90%)
* Data from [153]. This table was created using Cbioportal [165,166].
Large-scale molecular profiling by the Cancer Genome Atlas Research Network of 230 LUAD
samples from untreated patients revealed eighteen frequently mutated genes, including EGFR, KRAS,
STK11 and KEAP1 [219]. When pathway analysis was carried out, alterations in those linked to
oxidative stress were found in 22% of tumours due to mutations in KEAP1 (mutated in 19%),
CUL3 (mutated in >1%) and NFE2L2 (mutated in 3%) [219]. Amongst 178 LUSC samples from
untreated patients, ten genes were found to be frequently mutated, including TP53, CDKN2A, PTEN,
PIK3CA, KEAP1 and NFE2L2 [220]. These data also revealed that LUSC have relatively few mutations in
EGFR and KRAS, which are commonly mutated in LUAD, but a relatively high frequency of mutations
in PTEN and PIK3CA. However, they highlighted that dysregulation in oxidative stress pathways,
as seen in the LUAD cases, was similarly observed in 34% of LUSC tumours, due to mutations (or copy
number alterations) in KEAP1 (mutated in 12%), CUL3 (mutated in 7%) and NFE2L2 (mutated in 19%).
The study also highlighted that mutations in KEAP1 and CUL3 are often loss-of-function mutations that
occur mutually exclusive to mutations in NFE2L2 [220]. Somatic mutations in NFE2L2 were found to be
clustered around those parts of the gene encoding the DLG and ETGE motifs, with this type of ‘hot spot’
mutational pattern considered characteristic of an oncogene [221]. Unlike mutations in NFE2L2,
somatic mutations in KEAP1 were found to be distributed throughout the gene, which represents the
mutational pattern associated with tumour suppressor genes [151,222]. Due to their wide distribution,
it is difficult to attribute a function to all the mutations in KEAP1; however, some have been studied such
as the R32Q mutant, which has been shown to drive carcinogenesis [217]. The majority of mutations in
KEAP1 do not affect the binding and ubiquitylation of NRF2 but somehow halt proteasomal degradation
of the transcription factor [222].
It is now recognised that mutations in KEAP1, NFE2L2, PTEN and EGFR rarely co-exist.
Mutations in NFE2L2 have been demonstrated to co-occur with PIK3CA mutations [223] and mutations
in TP53. By contrast, mutations in KEAP1 tend to co-occur with mutations in KRAS and STK11 [203].
This pattern of mutual exclusivity of some mutated genes with others is indicative of a level of
redundancy, with both mutations resulting in the same phenotype (see Tables 4–6 for co-occurrence
of mutations). Another point of divergence between KEAP1 and NFE2L2 mutations, is that those in
KEAP1 are more commonly associated with LUAD than LUSC [224]. Research has also revealed that
several mutations in KEAP1 are G>T transversions, which are characteristic mutations associated
with exposure to tobacco smoke, and may in part explain why KEAP1 mutations often co-occur
with KRAS mutations, which are also associated with smoking [150,196,225]. The co-occurrence of
KEAP1 and KRAS mutations suggests that KEAP1 mutations either affect NRF2 activity differently
than KRAS-stimulated overexpression of NRF2, or are affecting other signalling pathways that are
beneficial to the tumour.
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NFE2L2 4(2.4%) 80 (8.2%) Mutual exclusivity
CUL3 6 (3.5%) 33(3.4%) Co-occurrence
KRAS 41 (24.1%) 181 (18.6%) Co-occurrence
TP53 103 (60.6%) 672 (69%) Mutual exclusivity
PIK3CA 12 (7.1%) 82(8.4%) Mutual exclusivity
PTEN 6 (3.5%) 61(6.3%) Mutual exclusivity
STK11 39 (22.9%) 72 (7.4%) Co-occurrence
* Data from [153]. This table was created using Cbioportal [165,166].













KEAP1 6(6.7%) 155(15%) Mutual exclusivity
CUL3 5 (4.8%) 34(3.3%) Co-occurrence
KRAS 5 (4.8%) 217 (20.9%) Mutual exclusivity
TP53 88 (83.8%) 687 (66.1%) Co-occurrence
PIK3CA 12 (11.4%) 82 (7.9%) Co-occurrence
PTEN 5 (4.8%) 62 (6%) Mutual exclusivity
STK11 3 (2.9%) 108 (10.4%) Mutual exclusivity
* Data from [153]. This table was created using Cbioportal [165,166].













NFE2L2 5 (9.8%) 79 (7.2%) Co-occurrence
KEAP1 6 (11.8%) 156 (14.3%) Mutual exclusivity
KRAS 4 (7.8%) 218 (20%) Mutual exclusivity
TP53 42 (82.4%) 733 (67.1%) Co-occurrence
PIK3CA 6 (11.8%) 88 (8.1%) Co-occurrence
PTEN 4 (7.8%) 63 (5.8%) Co-occurrence
STK11 3 (5.9%) 108 (9.9%) Mutual exclusivity
* Data from [153]. This table was created using Cbioportal [165,166].
By comparison with mutations in KEAP1 and NFE2L2, CUL3 mutations have not attracted much
attention. Mutations in CUL3 co-occur with mutations in NFE2L2 in LUSC, suggesting that a mutation
in CUL3 might potentially influence other cellular functions besides those controlled by NRF2 [226].
CUL3 is a member of the cullin family of scaffold proteins that bind E2 ubiquitin-conjugating enzymes
and recruit protein substrates for ubiquitylation [227]. Whilst CUL3 binds the BTB domain of KEAP1,
there are over 200 BTB domain-containing proteins in humans, all of which may be bound by
CUL3 [226,228]. Therefore, some of the mutations in CUL3 may not affect NRF2 degradation but that of
oncogenic proteins, implying that mutations in CUL3 may enhance oncogenesis independently of NRF2.
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Also, the wide range of potential CUL3-binding partners, which will affect a wide range of signalling
pathways, may explain the lower frequency of CUL3 mutations than NFE2L2 or KEAP1 mutations [226].
Targeted therapies for patients with mutations in specific genes, such as EGFR and BRAF, have had
very promising results in LUAD [219], but due to the genetic diversity between the different histotypes
of NSCLC, such therapies are not applicable for LUSC [220]. One caveat of the analyses carried out by
TCGA is that samples analysed were collected from patients with early-stage disease [229]. Research has
now shown that mutations in KEAP1 and NFE2L2 are often associated with late-stage metastatic
disease [230], with stage-4 cancer patients showing higher NRF2 activity than stage-3 patients [231].
When comparing the impact of mutations in NFE2L2 or KEAP1 on expression of NRF2-target genes,
mutations in NFE2L2 were found to result in overexpression of more genes compared to mutations in
KEAP1, suggesting that amino acid substitutions within the transcription factor are a more robust way
for the tumour to command a comprehensive oxidative stress response [218].
Since mutations in KEAP1 and NFE2L2 do not co-exist, there appears to be a segregation of each
with regard to how NRF2 upregulation enhances or supports different driver mutations. In view of
the fact that NRF2 upregulation is not associated with cancer initiation, but with tumour progression,
it would be reasonable to suggest that the mutation in KRAS, or TP53, arises as an early event that
precedes mutation in KEAP1, or mutation in NFE2L2, respectively. This has been highlighted by the
findings that KRAS mutant tumours with co-occurring KEAP1 mutations are associated with later
stage lung cancer [203].
10.2. Upregulation of NRF2 in Oesophageal Tumours
Oesophageal cancer is the 7th most common form of malignant disease worldwide [214]. It can
be divided epidemiologically into two subtypes, namely adenocarcinoma (EAC) and squamous cell
carcinoma (ESCC). ESCC is the more prevalent, and is associated with environmental exposure to alcohol
and cigarette smoke, implicating a strong contribution by ROS to the disease [232]. ESCC patients
receive chemoradiotherapy in the form of radiation combined with 5-fluorouracil or a platinum-based
agent [233]. The genetic components of ESCC have been extensively characterized. Next-generation
sequencing and whole exome sequencing studies have revealed mutations in TP53 (most mutated
gene in ESCC), NOTCH1, PIK3CA, TGFBR2 and NFE2L2 [232,234].
In ESCC, the somatic mutations in NFE2L2 cluster to regions of the gene encoding amino acids in
NRF2 associated with the KEAP1-binding sites, similar to mutations found in LUSC. Interestingly,
unlike other cancers with high NRF2 activity, KEAP1 mutations rarely occur in ESCC. Also, mutations in
CUL3 were rarely observed [154,235]. NFE2L2 mutations co-occur with mutations in TP53 and NOTCH1,
but are mutually exclusive with mutations in PIK3CA [235]. However, due to their low frequency in
ESCC, we cannot assess the co-occurrence of KEAP1 and CUL3 mutations with mutations in other genes.
NRF2 activity is commonly upregulated in ESCC tumours and cells lines [236]. This high incidence
in NRF2 upregulation cannot be attributed solely to mutations in NFE2L2, KEAP1 and CUL3, nor can
it be attributed to mutation of oncogenic driver genes KRAS, BRAF and MYC that increase NFE2L2
expression [154,232,235]. Rather, this unexpectedly high incidence of NRF2 upregulation may be
due to altered expression of microRNAs (miRs) that target NFE2L2 and KEAP1 expression; these are
small endogenous non-coding RNAs that can regulate gene expression by altering translation or
stability of a target through directly binding to the 3′-untranslated region (UTR) or coding region,
and can, therefore, regulate gene expression and tumour progression by functioning as tumour
suppressors/oncogenes [237]. Several miRs that exhibit altered expression in ESCC are able to regulate
the activity of either NRF2 or KEAP1, and may provide an alternative route by which the expression
of NRF2-target genes can be enhanced in ESCC tumours lacking NFE2L2 mutations. For example,
miR-200a directly targets KEAP1, increases NRF2 protein abundance and NRF2 nuclear accumulation
in ESCC cells [238]. The tumour suppressor miR-153-3p directly binds to the 3′ UTR of NRF2 inhibiting
its expression [237], and miR-432-3p downregulates KEAP1 expression by directly targeting the
coding region [168].
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Elevated NRF2 abundance and expression of the NRF2-target genes GCLC and NQO1 have been
found in both ESCC tumours and cell lines, and are associated with poor patient survival [239,240].
The exact timing at which NRF2 activity is elevated in oesophageal carcinogenesis has not been
determined but analysis of in situ ESCC tumours revealed the absence of NFE2L2 mutation,
suggesting that these mutations may not be associated with the initial stages of ESCC cancer but may
occur later to influence cancer progression [239].
10.3. Upregulation of NRF2 in Liver Tumours
The liver is the primary site of detoxification in the human body and is a metabolically active
organ that is exposed to substantial levels of oxidative stress [241]. Hepatocellular carcinoma (HCC)
is the 6th most common cause of cancer associated mortality worldwide [214]. There are several
well-documented risk factors associated with the development of HCC, these include exposure to
viral hepatitis B or C, high alcohol intake, diabetes, non-alcoholic fatty liver disease and liver cirrhosis,
which contribute to the development of 80–90% of all HCC [242,243]. Analysis of somatic mutations
present in HCC revealed a high frequency of mutations in TERT (most commonly mutated gene),
CTNNB1, TP53 and ARID1A [244].
Mutations in NFE2L2, that specifically cluster to regions of the gene encoding amino acids in
NRF2 that bind KEAP1, have been documented in early preneoplastic liver lesions and HCC tumour
samples [245]. KEAP1 mutations also occur in HCC tumours and when mapped, are found throughout
the gene [155]. Interestingly, the mutational frequency in NFE2L2 and KEAP1, 3% and 5% respectively,
is much lower than in some other cancer types [244]. Also, CUL3 mutations were not found in
the datasets analysed. NFE2L2 mutations and KEAP1 mutations were found to both co-occur with
mutations in TP53, CTNNB1 and ARID1A, but not with mutations in TERT [155,246].
Autophagy has been proposed to play a key role in protecting the liver against disease by
preventing the accumulation of damaged cytoplasmic proteins and organelles [247]. It is thought to
protect against the initiation of carcinogenesis and is frequently impaired during HCC, leading to
diminished clearance of cellular constituents. Inappropriate activation of the Hippo signalling
pathway effector Yes associated protein 1 (YAP1), which acts as a transcriptional coactivator of
TEA domain (TEAD) family members 1–4 (TEAD1-4) and so influences expression of genes that
control cell survival, proliferation and polarity, occurs as an early event during the development
of HCC [248]. The activation of YAP1 during early HCC development is thought to be due to its
reduced degradation by autophagy [249]. Besides YAP1, autophagy positively controls NRF2 by
virtue of the fact that the autophagy cargo receptor p62/SQSTM1 binds KEAP1 and by suppressing
KEAP1 increases NRF2 activity [134]. It is now recognised that under conditions of oxidative stress,
p62/SQSTM1 is phosphorylated at Ser351 by either TBK1 or CK2, which enhances binding between
KEAP1 and p62/SQSTM1, preventing KEAP1 binding to NRF2, leading to NRF2 nuclear accumulation
and induction of ARE-driven genes [250]. From these findings, it might be anticipated that loss of
autophagy during early stages of HCC would result in accumulation of KEAP1 and downregulation of
NRF2, but this does not seem to be the case. Presumably, loss of autophagy results in an increase in
p62/SQSTM1 as well as KEAP1, which blunts the ability of KEAP1 to target NRF2 for proteasomal
degradation. Indeed, the interaction between p62/SQSTM1 and KEAP1 is thought to provide HCC cells
with protection against ferroptosis by increasing the expression of members of the ARE-gene battery
that are critical to iron and ROS metabolism [251]. Also, of relevance, is that in instances of HCC that
involve hepatomegaly, NRF2 supports liver growth that is associated with enhanced glycogenosis and
PKB/Akt signalling [185]. Further work is required to translate the mouse-based experimental work on
autophagy in HCC to the clinical setting.
High levels of oxidative stress have been implicated in the development of HCC, potentially through
dysregulation of autophagy and upregulation of NRF2 [241]. The stage of cancer at which mutations in
NFE2L2 and KEAP1 arise is currently unknown. However, it has been shown that mutations in NFE2L2
occur in the early stages of HCC, and whilst the prevalence of NFE2L2 mutations decreases as the
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disease increases in severity, NRF2 activity remains heightened throughout HCC progression [252].
Potentially, this is due to high levels of oxidative stress leading to phosphorylation of p62/SQSTM1,
which allows it to compete for binding to KEAP1, resulting in increased NRF2 activity in the later
stages of HCC. Whether there is any difference between NRF2 activation occurring through somatic
mutations or through alternative routes is currently unknown.
10.4. Upregulation of NRF2 in Head and Neck Tumours
Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of cancer
worldwide, and has a poor associated survival [253]. HNSCC represents a heterogenous group of
malignant diseases that includes cancer of the oral cavity, oropharynx, nasopharynx, hypopharynx,
larynx, soft tissue of the neck, salivary glands and mucosal membranes [254]. Several etiological factors
have been linked to HNSCC, including tobacco use, alcohol consumption and human papilloma virus
(HPV) status [255]. Whole exome sequencing of HNSCC samples has shown a high frequency of
mutations in TP53, CDKN2A, FAT1 and PIK3CA [156].
NFE2L2 and CUL3 mutations have been identified in HNSCC at a frequency of 6% and 4%,
respectively, with mutations in NFE2L2 mapping onto regions encoding the Neh2 domain of NRF2 and
mutations in CUL3 occurring in regions encoding amino acids 33–66 in the CR1 domain. Mutations in
KEAP1 are rare and when they occur, are spread throughout the coding region [156].
Mutations in NFE2L2 co-occur with mutations in all the commonly mutated genes found in HNSCC,
whereas CUL3 mutations co-occur with mutations in TP53, PIK3CA and FAT1 but not CDKN2A [156].
Aside from somatic mutations, NRF2 may be upregulated in HNSCC due to the presence of copy number
amplifications in NFE2L2, copy number deletions in CUL3 and hypermethylation of KEAP1 [156,256].
Proteomic profiling revealed an NRF2 gene signature in HNSCC that is associated with poor
patient survival and increased NRF2 target gene expression, particularly HMOX1, GSTs and AKRs [254].
Although HNSCC encompasses a wide range of tumours that differ dramatically not only physically
but genetically, additional diversity is provided by etiological factors such as HPV. In tumours of
patients that are HPV-negative, high frequencies in mutation of TP53 is observed, whereas the opposite
is seen in tumours of HPV-positive patients [257]. As data suggest, NFE2L2 mutations tend to co-occur
with TP53 mutations, this would suggest they are associated with HPV-negative tumours. Work by
Victor Martinez and colleagues specifically focused on the consequences of NRF2 upregulation in
HNSCC, and found that whilst somatic mutations in NFE2L2 and KEAP1 are rare events, they are
associated with poor outcome [256]. Treatment failure in HNSCC patients has also been linked to
the presence of cancer stem cells, which are a small population of cells that can rapidly proliferate,
are resistant to apoptosis and exhibit increased NRF2 abundance [258].
10.5. Upregulation of NRF2 in Gastric Tumours
Gastric cancer (GC) is the 5th most common cause of cancer worldwide and more prevalent
in the male population [214]. Risk factors associated with the development of GC include dietary
factors such as salt consumption and vitamin A and vitamin C levels, chronic atrophic gastritis,
and Helicobacter pylori (H. pylori) infection [102]. Oxidative stress has also been implicated in GC
development by damaging DNA and causing mucosal injury. Studies into the genetics of GC have
revealed a high frequency of mutations in TP53 (most commonly mutated gene), LRP1B, AIRD1A,
PCLO and PIK3CA [155,157].
Molecular profiling of stomach adenocarcinoma patient tissues has identified mutations in
KEAP1, NFE2L2 and CUL3, with KEAP1 mutations being the most prevalent [155,157]. Interestingly,
mutations in NFE2L2 do not map to parts of the gene encoding the Neh2 domain of NRF2, and so
might be passenger mutations. Somatic mutations in KEAP1 and CUL3 map to amino acids throughout
the KEAP1 protein and to the CR1 domain of CUL3. Mutations in KEAP1 and CUL3 co-occur with
mutations in TP53 and PIK3CA. NFE2L2 mutations are mutually exclusive with mutations in TP53 but
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also co-occur with PIK3CA mutations, though it should be noted there were very few samples with
NFE2L2 mutations in these studies.
As increased nuclear levels of NRF2 protein have been documented in gastric cancer cell lines and
tissues [259], but the frequency of somatic mutations in NFE2L2, KEAP1 and CUL3 is low, it is likely
that NRF2 can be upregulated by other mechanisms in GC. Analyses by the Cancer Genome Atlas
Research Network has revealed that GC patients with copy number amplifications in NFE2L2 often
harbour mutations in TP53 and exhibit copy number amplification in PIK3CA. Deletions in KEAP1
were also found in some GC patients and tended to co-occur alongside TP53 mutations. High levels of
NRF2 mRNA and protein have been found in GC tissue in comparison to control tissues and have
been linked with clinicopathological features such as tumour size and drug resistance [259].
10.6. Upregulation of NRF2 in Bladder Tumours
Urinary bladder cancer (UBC) is responsible for a large number of cancer-associated deaths per
year world-wide and is 4-times more common in men than women [260]. UBC can be broadly divided
into two groups as follows: an early stage, low grade (commonly T1) non-invasive and more prevalent
group called non-muscle invasive bladder cancer (NMIBC); a late stage, high grade (commonly T3/T4)
invasive and more rare type called muscle invasive bladder cancer (MIBC) [261]. Risk factors for
the development of UBC include cigarette smoke, arsenic exposure, inhalation of diesel fumes and
aging [260,261]. Interestingly, molecular profiling has revealed that different genes are somatically
mutated in NMIBC and MIBC. MIBCs have a high frequency of mutations in TP53, RB1 and unstable
genomes, whereas NIMBCs have mutations in FGFR3, KDM6A and stable genomes, and both groups
often have CDKN2A deletions [262].
Mutations in the Neh2 region of NFE2L2 have been found in MIBCs (particularly associated
with patients that have a history of smoking) and are thought to increase NRF2 activity [158,263].
KEAP1 is mutated less frequently than NFE2L2 and the mutations spread throughout the gene. CUL3 is
not mutated in MIBCs but copy number deletions occur [158]. Data from the Cancer Genome Atlas
Research Network has shown that TP53 is commonly mutated in MIBCs [158,262], which again
supports the idea that NFE2L2 mutations may co-occur with mutations in specific driver genes. In the
case of UBC, TP53 mutations are very prevalent in MIBCs, which is the subtype of UBC that have
NFE2L2 mutations. However, there are not enough data to support this association currently.
The stress-inducible scaffold protein p62/SQSTM1 is over-expressed in both UBC cell lines and
tissues leading to increased NRF2 activation and protection of the cancer cells against oxidative
stress [264]. The phagocytosis-related protein GULP1 is often decreased in UBC cell lines and tissues
due to epigenetic alterations. Silencing of GULP1 leads to increased NRF2 activity and the emergence
of drug resistance. GULP1 has now been shown to bind directly and stabilize KEAP1 protein locking it
bound to NRF2 in the cytoplasm [265]. Also, exposure to several different carcinogens has been linked
to the development of bladder cancer and the inactivation and transport of such compounds often
involves UGT and GST enzymes, the genes of which are NRF2 targets [261].
NRF2 is upregulated in UBC, specifically in MIBCs which are the late-stage more aggressive
invasive form of the disease. This suggests that in UBC, increases in NRF2 activity through somatic
mutations occurs in the transition from early-stage to late-stage disease, to support carcinogenesis
after it has become established. By contrast, Nrf2-ko mice are more susceptible to carcinogen-induced
UBC than are wildtype mice, suggesting that Nrf2 may also have an anti-cancer effect during disease
initiation [91] and expression of the Nrf2-target gene Gstp1 has been implicated in the detoxification of
compounds that induced UBC [261].
10.7. Upregulation of NRF2 in Colorectal Tumours
Colorectal cancer (CRC) is the 3rd most common cancer worldwide, with more cases being
diagnosed each year [214]. 5-Fluorouracil is the current standard treatment for the disease but is
associated with high levels of acquired drug resistance [266]. There are several known prognostic factors
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associated with CRC, including the side of the colon on which the tumour is located, mutational status
of driver genes (such as KRAS and BRAF), epigenetic modifications, genomic instability and DNA
mismatch repair status (due to mutations in MLH1, MLH3, MSH2, MSH3, MSH6 and PSM2) [267].
Molecular profiling of early- and late-stage metastatic CRC has identified a high frequency of somatic
mutations in APC (most mutated gene), KRAS, BRAF, TP53, PIK3CA and SMAD4 [159,268].
Mutations in NFE2L2 rarely occur in CRC and when the mutations are mapped onto the
NRF2 protein they are distributed throughout the primary structure, suggesting they probably
represent passenger mutations. KEAP1 mutations are also infrequent and occur throughout the gene.
CUL3 mutations were not present in the dataset [159]. Due to their low frequency in the case of
NFE2L2 mutations and their absence in the case of CUL3 mutations, their co-occurrence with other
mutations in CRC cannot be estimated. Missense mutations in KEAP1 co-occur with mutations in
BRAF, PIK3CA and APC but are mutually exclusive from mutations in KRAS and TP53 [159].
Similar to oesophageal cancer, the high levels of NRF2 activity found in CRC do not correlate with
the presence of KEAP1 and NFE2L2 mutations, which are relatively rare according to analysis
by the Cancer Genome Atlas Research Network of somatic mutations in CRC. Nevertheless,
NRF2 is upregulated in CRC tumours, and high levels of nuclear NRF2 protein correlate with
poor prognosis [269], suggesting a role in tumour progression. One possible explanation for the
upregulation of NRF2 in this instance is DNA methylation: this is an epigenetic process by which an
addition of a methyl group to DNA alters gene expression, and if CpG islands located in the gene
promoter are methylated, chromatin remodelling may occur that leads to repression of transcription.
High levels of methylation of the KEAP1 gene promoter have been observed in human CRC cell
lines and tumour samples, leading to lower levels of KEAP1 mRNA, increased NRF2 protein and
over-expression of its target genes [267,270]. Conversely, demethylation of a CpG island in the promoter
of NFE2L2 has been identified in CRC tumour samples. Whereas, the same site has been shown
to be methylated in pre-cancerous colorectal polyps suggesting that the demethylation of NFE2L2
may influence carcinogenesis [271]. As KRAS and BRAF mutations are prevalent in CRC, NRF2 may
frequently be upregulated by transcriptional activation of NFE2L2, as reported in mouse models of
pancreatic cancer [164].
CRC is thought to be strongly driven by ROS. APC mutations that lead to the activation of WNT
signalling are one of the earliest initiation events in CRC and are associated with the generation of both
the superoxide anion radical (O2•–) and H2O2 [272]. Also, in the human colorectal HCT116 cancer
cell line, nitric oxide, which is produced during inflammation, has been shown to lead to nuclear
accumulation of NRF2, potentially through modification of key reactive cysteine residues in KEAP1 [273].
Consistent with the likely contribution of ROS to the development of CRC, inflammation has been
shown to be a significant risk factor, with inflammatory bowel disease patients having a higher chance
of developing the disease [272].
High levels of NRF2 activity and overexpression of its target genes are associated with later stage
and poorer patient survival in CRC [267,274]. In the clinical setting, this might in part be explained
by the fact that high levels of NRF2 have been implicated in the development of resistance against
5-fluorouracil [275]. It is thought that increases in NRF2 activity provide cytoprotection to premalignant
adenomatous cells in the early stages of carcinogenesis [275] and that once the cancer is established
high levels of NRF2 will support tumour progression.
11. Therapeutic Approaches to Treat Tumours in Which NRF2 Is Upregulated
As cancer chemopreventive blocking agents protect normal tissues against initiation of
carcinogenesis by inducing NRF2-target genes encoding enzymes that minimise the genotoxic and
cytotoxic effects of carcinogens, it is not surprising that the permanent activation of NRF2 in tumour
cells confers resistance to therapeutic agents, as well as radiotherapy. Because NRF2 can mediate
cancer chemoprevention and also support tumour promotion/progression, it has been referred to as
a ‘doubled-edged sword’ [122]. The potentially adverse effects of NRF2 activation in pre-neoplastic
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lesions and in tumour cells are well recognised and have been referred to by Donna Zhang’s laboratory
as the ‘dark side’ of the transcription factor [165–167,276]. This is also reflected by the fact that in
the clinical setting, upregulation of NRF2 is associated with poor prognosis and decreased overall
survival in patients with lung cancer [277], head and neck cancer [254], oesophageal cancer [233],
gastric cancer [278], liver cancer [279] and colorectal cancer [267,269].
As cancer cells are potentially more sensitive to oxidative stress than normal cells, because of
their high ROS burden caused by oncogene activation, NADPH oxidase activation and mitochondrial
dysfunction, therapeutic strategies to augment ROS production or diminish their antioxidant capacity
have been considered as a means of producing selective toxicity in tumours [280]. For example,
from a large chemical screen, a class of drugs that induced oxidative stress was identified because
of their selective toxicity towards KrasG12D-expressing MEFs, with lanperisone being the most
potent and shown to increase ROS production and stimulate non-apoptotic death [281]. In terms
of suppressing the GSH-based antioxidant system, inhibition of the GCLC/GCLM heterodimeric
enzyme by buthionine sulfoximine, inhibition of GSR1 by 2-acetylamino-3-[4-(2-acetylamino-2-
carboxyethylsulfanylthiocarbonylamino)phenylthiocarbamoyl-sulfanyl]propionic acid (2-AAPA),
and inhibition of the SLC7A11 antiporter by sulfasalazine or erastin, have been proposed as means of
sensitizing tumour cells to chemo- and radiotherapy [282]. In addition, suppressing the TXN-based
antioxidant system by targeting TXN using PX-12 and targeting TXNRD using auranofin or motexafin
gadolinium have also been proposed to sensitise tumours to radiotherapy.
In tumour cells that utilize heightened levels of ROS to drive proliferation, it has been pointed out
that the demands of maintaining high antioxidant levels in order to avoid cell death places pressure on
their intracellular pools of glutamate, cysteine and glycine, required to produce GSH, and which in
turn results in an increased dependency on an exogenous supply of glutamine, serine and asparagine
required to meet such demands [283,284]. Consequently, tumour cells that require high GSH levels
for survival are potentially more sensitive than normal cells to glutaminase inhibitors that prevent
glutamine from being converted to glutamate, which would in turn be used by SLC7A11 to import
cystine into cells [283]. Indeed, these workers have proposed that tumour cells with upregulated
NRF2 have increased dependency on exogenous non-essential amino acids, and that depletion of
non-essential amino acids in the microenvironment preferentially inhibits proliferation of MEFs
lacking Keap1 [284].
The most obvious way of treating tumours harbouring mutations in NFE2L2 or KEAP1 is with
drugs that inhibit NRF2 activity, and a range of small molecules have been reported to possess
this ability. Arguably the best-known example of this strategy is provided by the quassinoid
brusatol [285], whilst other examples include retinoic acid [286] or the natural flavonoids luteolin and
wogonin [287,288]. These molecules all suffer from issues of specificity and confounding off-target
effects, with brusatol inhibiting global protein translation [289]. A number of academic research
groups have screened various chemical libraries for small molecules that inhibit NRF2 activity,
using a variety of cell-based reporter assays. Using ARE-driven luciferase assays, compounds such as
4-(2-cyclohexylethoxy)aniline [290], ML385 [291], halofuginone [292] and clobetasol propionate [293]
have been identified as effective inhibitors of NRF2 activity. It is not clear how many of these will be of
value in clinical practice.
Since upregulation of NRF2 increases NADPH levels within cells, reductive bioactivation of
drugs might be considered a potentially effective strategy to treat cancer cells harbouring mutations in
NFE2L2, KEAP1, or CUL3. Of particular relevance in this regard is the enzyme NQO1, which is often
overexpressed in rat liver preneoplastic nodules and human tumours (reviewed in [145,294,295]) where
it may be capable of bioreductive activation of quinone-containing xenobiotics. The first compounds
recognised to be subject to NQO-mediated activation included 5-(aziridine-1-yl)-2,4-dinitrobenzamide
(CB1954, also known as Tretazicar) and mitomycin C, both of which are activated to bifunctional
alkylating agents that can cross-link DNA (Figure 6) [296–299].
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Subsequently, it has been found that activation of CB1954 is catalysed by NQO1 in rat cells and
NQO2 in human cells [300,301]. Following the demonstration that NQO1 activates mitomycin C,
Dave Ross and colleagues discovered that NQO1 is capable of activating a range of antitumour quinones,
including streptonigrin, 2,5-diaziridinyl-3-phenyl-1,4-benzoquinone, 2,5-diaziridinyl-3,6-dimethyl-1,4-
benzoquinone and [3-hydroxymethyl-5- aziridinyl-1-methyl-2-(1H-indole-4,7-dione)-propenol] [302,303].
Some of these compounds are now being investigated in clinical trials [304,305] but more development
is necessary for them to be used in the clinic. It should be mentioned that a potentially valuable use
of NQO1-bioactivatable agents is their ability to synergise with PARP1 inhibitors and radiotherapy,
thereby allowing a reduction in dose of agents administered and minimisation of unwanted toxic
side effects [306].
An alternative strategy to exploiting the overexpression of NQO1 to reductively activate antitumour
drugs is that of stimulating cytotoxic levels of ROS production, through futile NQO1-catalysed
redox-cycling of quinone-containing compounds such as the naturally-occurring 1,2-naphthoquinone
β-lapachone [307], and the more potent synthetic compound deoxynyboquinone [308]. Notably,
however, despite overexpression of NQO1, cells with upregulated NRF2 may be resistant toβ-lapachone
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due to enhanced detoxification of ROS, though this can be overcome by inhibition of TXNRD or
SOD1 [269]. Other deoxynyboquinone-related compounds, DNQ-7 and IB-DNQ, have also been
reported to stimulate death in an NQO1-associated manner [295].
The benzoquinone-containing compound 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)
and the related 17-DMAG, are examples of drugs that NQO1 activates by catalysing their reduction to
a hydroquinone ansamycin, which inhibits heat shock protein 90 (HSP90) and destabilises mutated
oncogenic proteins in cancer cells such as protein kinases, steroid receptors and transcription
factors [309,310]. Interestingly, it has been found that 17-AAG is significantly more toxic to mouse
Hepa1 cells with upregulated Nrf2, from knockout of Keap1, than those in which regulation of the
transcription factor by Keap1 is intact, and this increased toxicity is dependent on the quinone moiety
within the geldanamycin scaffold because HSP90 inhibitors lacking this structure were not more toxic
to cells in which NRF2 is upregulated [311]. It has, therefore, been proposed that reduction of the
17-AAG quinone to the 17-AAGH2 hydroquinone, catalysed by overexpressed Nqo1, resulted in
more potent inhibition of Hsp90 that resulted in cell death, though other ‘off-target’ explanations are
possible. More recently, Liam Baird and colleagues have used their cell-based differential survival
screen to identify other small molecules that display selective toxicity towards Hepa1 cells lacking
Keap1. Remarkably, from amongst currently-approved drugs, they identified mitomycin C as an
agent that displays preferential toxicity towards cells in which Nrf2 is permanently upregulated,
and demonstrated that this is likely to be due to overexpression of Nqo1 and enzymes that generate
NADPH via the PPP, all of which are encoded by Nrf2-target genes [312]. They also demonstrated
that administration of mitomycin C along with 17-AAG led to synergistic toxicity and suggested that
as activation of mitomycin C would lead to DNA damage and activation of 17-AAG would lead to
proteotoxic stress that the combination represented ‘concurrent synthetic lethality’.
Unfortunately, 17-AAG may be poorly tolerated by patients due to liver and lung toxicity,
which results from redox cycling and/or arylating nucleophilic centres within the cell. To avoid such
effects, which involves the 19-position on the quinone ring adjacent to one of the carbonyls, a series of
19-substituted benzoquinone ansamycins (19-BQAs) have been created [313]. These were found not to
react with GSH, were subject to less redox cycling than 17-DMAG and exhibited less hepatotoxicity
than DMAG [314]. It remains to be seen whether 19-BQAs are more toxic to cancer cells in which NRF2
is upregulated.
12. Concluding Comments
Herein, we have described the background to the discovery that NRF2 is responsible for intrinsic
resistance to many chemical carcinogens and that through its ability to mediate cellular adaption to
oxidative and electrophilic stress it orchestrates induction of cytoprotective detoxification genes by
cancer chemopreventive agents, thus inhibiting initiation of carcinogenesis in stomach, bladder, skin,
GI tract, breast, lung and liver. We also recount events that led to the recognition that NRF2 is frequently
upregulated in tumour cells, and describe a wide range of mechanisms that allow it to escape repression
by KEAP1, with somatic mutations in NFE2L2, KEAP1 and CUL3 being the best characterized examples.
From screening work done through TGCA, it has become clear that NRF2 upregulation is a feature
of many common cancers, including those of lung, oesophagus, liver and head and neck. Whilst it
might have been anticipated that tissues in rodents in which chemopreventive agents protect against
carcinogenesis would be the same as those in which NRF2 is permanently upregulated in human
tumours, because NRF2 function is necessary for adaptation in such tissues, this was found to be
only partially true. There are at least three reasons for this disparity: firstly, the NRF2-mediated
mechanisms responsible for chemoprevention (increased detoxification) differ from those NRF2 confers
during tumour progression (increased ROS scavenging, generation of NADPH, synthesis of serine and
synthesis of ribonucleotides); secondly, as NRF2 can be upregulated by mechanisms other than somatic
mutations in NFE2L2, KEAP1 and CUL3, the full extent to which NRF2 is constitutively activated
in cancer is not known; thirdly, the demands placed on NRF2 to support growth and survival of
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cells harbouring mutations in genes that drive tumourigenesis are highly variable across different
cancer types.
Evidence from studies of the rat Solt-Farber hepato-carcinogenesis model and clinical NSCLC
samples suggest that upregulation of NRF2 occurs early during tumourigenesis, and that its constitutive
activation probably supports the actions of oncogenic KRAS and hyperactivated PKB/Akt. However,
whilst these studies might be interpreted to indicate NRF2 upregulation is less important in late stages
of cancer than in the early promotion/progression stages, this does not seem to be universally true.
For example, mutations in KEAP1 and NFE2L2 have been reported in late-stage bladder cancer and
NRF2 has been reported to be upregulated in a model of post-therapy recurrence of breast cancer.
Moreover, whilst it is well recognised that NRF2 upregulation benefits tumours because it provides
protection against ROS-stimulated cell death and supports cell proliferation during all stages of cancer
evolution, its putative ability to modulate the innate immune system may be important in late stage
cancer. Clearly, more work is required to establish why NRF2 upregulation occurs in later progression
and metastatic stages of disease.
As upregulation of NRF2 frequently confers upon tumours resistance to chemo- and radio-therapy,
strategies are urgently required to overcome such resistance. To this end, a variety of ROS-based and
quinone-based pharmacological approaches that capitalise on overexpression of NRF2-target genes
are described, but more developmental work is required to generate drugs that are clinically useful.
The functional and regulatory inter-relationships between NRF2 and other antioxidant transcription
factors such as AP-1, FOXO, PGC-1α, NF-κB and TP53 during the various stages of tumourigenesis
is not understood, and this issue needs to be addressed for us to appreciate fully the importance of
redox signaling during the different stages of tumourigenesis; this is likely to be important in tumours
with mutant TP53. Understanding the contributions made by NRF2 to tumourigenesis has enabled
new diagnostic and prognostic tools to be developed and provides a strong rationale for effective
therapeutic strategies to overcome drug resistance.
One of the major obstacles in studying the course of events that occurs during the evolution of
cancer is the large amount of cellular heterogenicity observed in tumours. Previously, transcriptomic
analysis has been limited to examining populations of cells, but the development of single cell
sequencing technology now allows the analysis of individual cells and has been used to address
the question of heterogenicity in several cancer types [315,316]. Studying the impact of mutations
in NFE2L2, KEAP1 and CUL3 will be made possible through the use of precise techniques such as
Base Editors [317] and Saturation Genome Editing [318], which can be used to generate specific
point mutations. These techniques, in combination with high-throughput screening technologies,
will allow the field to address important questions surrounding the impact of mutations in NFE2L2,
KEAP1 and CUL3. Currently, studies using these techniques are limited due to the high associated cost,
but hopefully as the technology develops and the cost reduces, such technology will become more
accessible to researchers in the field [316]
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